JP2023538408A5 - - Google Patents
Info
- Publication number
- JP2023538408A5 JP2023538408A5 JP2023512462A JP2023512462A JP2023538408A5 JP 2023538408 A5 JP2023538408 A5 JP 2023538408A5 JP 2023512462 A JP2023512462 A JP 2023512462A JP 2023512462 A JP2023512462 A JP 2023512462A JP 2023538408 A5 JP2023538408 A5 JP 2023538408A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- halo
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068870P | 2020-08-21 | 2020-08-21 | |
| US63/068,870 | 2020-08-21 | ||
| PCT/US2021/047015 WO2022040600A1 (en) | 2020-08-21 | 2021-08-20 | Compounds as glp-1r agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538408A JP2023538408A (ja) | 2023-09-07 |
| JP2023538408A5 true JP2023538408A5 (enExample) | 2024-08-26 |
Family
ID=80350630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512462A Pending JP2023538408A (ja) | 2020-08-21 | 2021-08-20 | Ｇｌｐ－１ｒ作動薬としての化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230322744A1 (enExample) |
| EP (1) | EP4199919A4 (enExample) |
| JP (1) | JP2023538408A (enExample) |
| KR (1) | KR20230074486A (enExample) |
| CN (1) | CN116507326A (enExample) |
| AU (1) | AU2021327397A1 (enExample) |
| BR (1) | BR112023003168A2 (enExample) |
| CA (1) | CA3192601A1 (enExample) |
| CL (2) | CL2023000516A1 (enExample) |
| CO (1) | CO2023003322A2 (enExample) |
| IL (1) | IL300795A (enExample) |
| MX (1) | MX2023002108A (enExample) |
| PE (1) | PE20231206A1 (enExample) |
| TW (1) | TWI905252B (enExample) |
| WO (1) | WO2022040600A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4204415A4 (en) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CR20230330A (es) * | 2021-01-28 | 2023-11-15 | Carmot Therapeutics Inc | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso |
| WO2022184849A1 (en) * | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| WO2022192428A1 (en) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) * | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20240208952A1 (en) * | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| JP7772778B2 (ja) * | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| CN117222631A (zh) * | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2023011539A1 (zh) * | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
| US20240374587A1 (en) | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250214968A1 (en) * | 2022-03-25 | 2025-07-03 | Ildong Pharmaceutical Co., Ltd. | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof |
| US20250136584A1 (en) * | 2022-05-20 | 2025-05-01 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof |
| CN120289354A (zh) * | 2022-07-18 | 2025-07-11 | 厦门市博瑞来医药科技有限公司 | 五元并六元化合物、其中间体、制备方法、组合物和应用 |
| JPWO2024063140A1 (enExample) * | 2022-09-22 | 2024-03-28 | ||
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| CN116102543B (zh) * | 2022-10-21 | 2025-07-22 | 江南大学 | 一种glp-1r激动剂、合成方法及其用途 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| TW202434574A (zh) * | 2023-02-02 | 2024-09-01 | 大陸商江蘇豪森藥業集團有限公司 | 一種環烯類化合物的鹽、晶型及其製備方法和應用 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202515865A (zh) * | 2023-09-21 | 2025-04-16 | 南韓商尹諾衛醫藥有限公司 | 製備取代的稠合咪唑衍生物的方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| DK3806855T5 (da) * | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| US11254660B2 (en) * | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| WO2021096284A1 (ko) * | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| EP4334304A1 (en) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| CN117715906A (zh) * | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
-
2021
- 2021-08-20 CA CA3192601A patent/CA3192601A1/en active Pending
- 2021-08-20 JP JP2023512462A patent/JP2023538408A/ja active Pending
- 2021-08-20 TW TW110130936A patent/TWI905252B/zh active
- 2021-08-20 PE PE2023000511A patent/PE20231206A1/es unknown
- 2021-08-20 MX MX2023002108A patent/MX2023002108A/es unknown
- 2021-08-20 AU AU2021327397A patent/AU2021327397A1/en active Pending
- 2021-08-20 US US18/042,443 patent/US20230322744A1/en active Pending
- 2021-08-20 US US17/445,588 patent/US20220089578A1/en not_active Abandoned
- 2021-08-20 KR KR1020237009681A patent/KR20230074486A/ko not_active Withdrawn
- 2021-08-20 BR BR112023003168A patent/BR112023003168A2/pt unknown
- 2021-08-20 CN CN202180071858.5A patent/CN116507326A/zh active Pending
- 2021-08-20 EP EP21859247.5A patent/EP4199919A4/en active Pending
- 2021-08-20 WO PCT/US2021/047015 patent/WO2022040600A1/en not_active Ceased
- 2021-08-20 IL IL300795A patent/IL300795A/en unknown
-
2023
- 2023-02-21 CL CL2023000516A patent/CL2023000516A1/es unknown
- 2023-03-17 CO CONC2023/0003322A patent/CO2023003322A2/es unknown
-
2024
- 2024-04-05 CL CL2024001025A patent/CL2024001025A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538408A5 (enExample) | ||
| JP2024541920A5 (enExample) | ||
| JP2024534621A5 (enExample) | ||
| CN105189453B (zh) | 氨磺酰基‑芳基酰胺及其作为用于乙型肝炎治疗的药物的用途 | |
| JP2023534983A5 (enExample) | ||
| JP6861703B2 (ja) | Ｔｇｒ５修飾物質およびその使用方法 | |
| JP2021508686A5 (enExample) | ||
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2016518429A5 (enExample) | ||
| JP2021512114A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2019532928A5 (enExample) | ||
| HRP20251161T1 (hr) | Benzimidazol karboksilne kisele kao agonisti glp-1r | |
| RU2017130466A (ru) | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения | |
| JP2009523841A5 (enExample) | ||
| JP2022500469A5 (enExample) | ||
| JP2025509697A5 (enExample) | ||
| JP2022541514A5 (enExample) | ||
| JP2022500473A5 (enExample) | ||
| JP2022507805A5 (enExample) | ||
| JP2022548250A5 (enExample) | ||
| WO2008117229A4 (en) | Muscarinic receptor antagonists | |
| JP2021533206A5 (enExample) | ||
| JP2021528451A5 (enExample) | ||
| JP2022541254A5 (enExample) |